• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Appendix Figure 21. KQ3 Total mortality sensitivity analysis—Meta-analysis of randomized placebo-controlled trials utilizing intention-to-treat methodologies in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure.

Appendix Figure 21KQ3 Total mortality sensitivity analysis—Meta-analysis of randomized placebo-controlled trials utilizing intention-to-treat methodologies in patients with stable ischemic heart disease who have recently undergone, or are set to undergo, a coronary revascularization procedure

Test for heterogeneity: Cochran Q=3.810035 (df=4) p=0.4323

I2 statistic=0%

Note: The squares represent individual point estimates. The size of the square represents the weight given to each study in the meta-analysis. Horizontal lines through each square represent 95% confidence intervals. The diamond represents the combined results. The solid vertical line extending from 1 is the null value.

From: Appendix C, Additional Evidence Tables and Analyses

Cover of Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease
Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease [Internet].
Comparative Effectiveness Reviews, No. 18.
Coleman CI, Baker WL, Kluger J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.